MEDraysintell Releases the Fifth Edition of Its Nuclear Medicine Report and Directory
New radiotheranostics under development might lead to much stronger market figures than expected in coming years.
Louvain-la-Neuve, Belgium, July 18, 2018 --(PR.com)-- MEDraysintell releases its new and fifth edition of the Nuclear Medicine World Market Report and Directory–Edition 2018, a 1,200-page document that provides an exhaustive description and analysis of almost 420 products, including over 150 radiopharmaceuticals under clinical development, with a comprehensive profile of 219 companies and institutions active in the radiopharmaceutical industry.
MEDraysintell estimates that the global market for nuclear medicine reached US$ 4.8 billion in 2017, growing by 7% from 2016. The market is expected to reach up to US$ 26 billion in 2030, a realistic figure that seems to be confirmed by major recent changes and investments in this area.
The strong growth of radiotherapeutics which represented 13% of the total nuclear medicine market in 2017, compared to 4% in 2013, still mainly driven by the success of Xofigo (Bayer) triggered the interest of many existing and new players. MEDraysintell anticipates that the global market will reach US$ 5.9 billion in 2019, with radiotherapeutics growing to 19% of the total nuclear medicine market. It is now expected that radiotherapeutics will represent more than 60% of the US$ 26 billion nuclear medicine market by 2030.
On an optimistic basis, figures for 2030 could even be higher as they are not taking in account the new therapeutic approaches that have been initiated over the past twelve months, and we prefer to wait confirmation of all these new investments before integrating in these figures their chances of success.
All these topics and much more are extensively covered in the new Nuclear Medicine Report & Directory, Edition 2018. The MEDraysintell Nuclear Medicine report has become the sole trusted source of intelligence in this industry and this fifth edition will prove once again to be the best advising tool for the pharmaceutical and radiopharmaceutical industry, investment organizations, international consulting firms, R&D laboratories to understand the market, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A) in this field.
About MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!
MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, written by specialists from the field, with over 2,200 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A). We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories. MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 70 years of experience in radiation healthcare. www.medraysintell.com
MEDraysintell estimates that the global market for nuclear medicine reached US$ 4.8 billion in 2017, growing by 7% from 2016. The market is expected to reach up to US$ 26 billion in 2030, a realistic figure that seems to be confirmed by major recent changes and investments in this area.
The strong growth of radiotherapeutics which represented 13% of the total nuclear medicine market in 2017, compared to 4% in 2013, still mainly driven by the success of Xofigo (Bayer) triggered the interest of many existing and new players. MEDraysintell anticipates that the global market will reach US$ 5.9 billion in 2019, with radiotherapeutics growing to 19% of the total nuclear medicine market. It is now expected that radiotherapeutics will represent more than 60% of the US$ 26 billion nuclear medicine market by 2030.
On an optimistic basis, figures for 2030 could even be higher as they are not taking in account the new therapeutic approaches that have been initiated over the past twelve months, and we prefer to wait confirmation of all these new investments before integrating in these figures their chances of success.
All these topics and much more are extensively covered in the new Nuclear Medicine Report & Directory, Edition 2018. The MEDraysintell Nuclear Medicine report has become the sole trusted source of intelligence in this industry and this fifth edition will prove once again to be the best advising tool for the pharmaceutical and radiopharmaceutical industry, investment organizations, international consulting firms, R&D laboratories to understand the market, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A) in this field.
About MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!
MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, written by specialists from the field, with over 2,200 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A). We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories. MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 70 years of experience in radiation healthcare. www.medraysintell.com
Contact
MEDraysintell
Paul-Emmanuel Goethals
+32 491 080 968
www.medraysintell.com
Richard Zimmermann
+33 6 82 80 06 00
Paul-Emmanuel Goethals
+32 491 080 968
www.medraysintell.com
Richard Zimmermann
+33 6 82 80 06 00
Contact
Categories